Original Articles a New Gene (DYX3) for Dyslexia Is Located on Chromosome 2

Total Page:16

File Type:pdf, Size:1020Kb

Original Articles a New Gene (DYX3) for Dyslexia Is Located on Chromosome 2 664 J Med Genet 1999;36:664–669 J Med Genet: first published as 10.1136/jmg.36.9.664 on 1 September 1999. Downloaded from Original articles A new gene (DYX3) for dyslexia is located on chromosome 2 Toril Fagerheim, Peter Raeymaekers, Finn Egil Tønnessen, Marit Pedersen, Lisbeth Tranebjærg, Herbert A Lubs Abstract skills, and adequate schooling.1 In 1950, Developmental dyslexia is a specific read- Hallgren2 reported that more than 80% of chil- ing disability aVecting children and adults dren with dyslexia in Stockholm schools had who otherwise possess normal intelli- other family members with dyslexia. Subse- gence, cognitive skills, and adequate quent studies have shown that there is both a schooling. DiYculties in spelling and physical and genetic basis for many children reading may persist through adult life. and adults with severe reading disability and Possible localisations of genes for dyslexia that the most frequent deficit is in phonological have been reported on chromosomes 15 coding.34This is manifested by decreased abil- (DYX1), 6p21.3-23 (DYX2), and 1p over the ity to pronounce letter strings (or pseudowords) last 15 years. Only the localisation to correctly that have not been encountered previ- 6p21.3-23 has been clearly confirmed and ously. Recent studies using new methods have a genome search has not previously been provided a clearer view of the diVerence in the carried out. We have investigated a large processing of written words in dyslexics and Norwegian family in which dyslexia is non-impaired readers. In none of the studies, inherited as an autosomal dominant trait. however, were the details of the family history A genome wide search for linkage with an known, and gene localisation studies were not average 20 cM marker density was initi- carried out. Using whole brain magnetoen- ated in 36 of the 80 family members. The cephalograpy,5 it was shown that in response to linkage analysis was performed under reading lists of real and non-words normal Department of three diVerent diagnostic models. Linkage readers first activated the posterior occipital http://jmg.bmj.com/ Medical Genetics, analysis in the family identified a region in cortex in 150 ms, then activated the left tempo- University Hospital of 2p15-p16 which cosegregated with dys- roparietal area by 184 ms. Six dyslexics, Tromsø, N-9038 lexia. Maximum lod scores of 3.54, 2.92, however, failed to activate the temporoparietal Tromsø, Norway and 4.32 for the three diVerent diagnostic region in the first 200 ms and instead activated T Fagerheim M Pedersen models were obtained. These results were the right or left inferior frontal gyrus. This L Tranebjærg confirmed by a non-parametric multi- region contains Broca’s area and its activation H A Lubs point GENEHUNTER analysis in which suggests the use of guessing as an alternative on September 24, 2021 by guest. Protected copyright. the most likely placement of the gene was processing strategy. Using functional magnetic Neurogenetics ina4cMinterval between markers resonance imaging (fMR)6 and a carefully con- Laboratory, D2S2352 and D2S1337. Localisation of a Department of structed, increasingly complex series of reading Biochemistry, Born gene for dyslexia to 2p15-16, together with tests, 29 dyslexics were found to show relatively Bunge Foundation, the confirmed linkage to 6p21.3-23, con- less posterior activation (including Wernicke’s University of Antwerp stitute strong evidence for genetic area, the angular gyrus, and striate cortex), and (UIA), Belgium heterogeneity in dyslexia. Since no gene increased activation anteriorly (inferior frontal P Raeymaekers for dyslexia has been isolated, little is gyrus), compared to non-impaired readers. known about the molecular processes Center For Reading These studies show the use of a diVerent Research, Stavanger, involved. The isolation and molecular processing pathway in response to phonological Norway characterisation of this newly reported tasks and the presence of an altered temporal F E Tønnessen gene on chromosome 2 (DYX3) and DYX1 response in dyslexics. In addition, impaired dis- will thus provide new and exciting insights crimination of both rapidly presented visual and Division of Genetics, into the processes involved in reading and Department of auditory non-verbal information have been 7–9 Pediatrics, Miami, FL, spelling. reported, and a more generalised defect in the USA (J Med Genet 1999;36:664–669) rapid processing of information may also play a H A Lubs Keywords: developmental dyslexia; reading disability; role in some or all instances of dyslexia. Many children under 2 years of age with Correspondence to: linkage analysis; chromosome 2 Dr Fagerheim. damage to the language areas of the left hemi- sphere can go on to develop satisfactory Revised version received Developmental dyslexia is a specific reading language ability. This observation implies that 28 April 1999 Accepted for publication disability aVecting children and adults who specialisation of the brain mechanism responsi- 5 May 1999 otherwise possess normal intelligence, cognitive ble for language function is not completed at A new gene for dyslexia is located on chromosome 2 665 J Med Genet: first published as 10.1136/jmg.36.9.664 on 1 September 1999. Downloaded from I ?? 81 79 79 70 77 76 76 74 70 64 II 1 2 43 65 7 8 91415 41 12 46 11 11 11 42 12 12 21 53 34 51 51 55 23 53 64 18 12 22 18 18 66 32 12 46 22 24 21 22 22 24 14 24 21 38 36 33 38 38 33 38 36 34 21 21 43 21 21 13 11 21 42 23 22 32 23 23 32 13 22 32 53 55 36 43 38 35 49 5047 39 44 47 41 36 35 34 32 30 III 1 34567 8 9 10 12 15 16 17 18 21 23 24 30 31 32 11 41 14 11 11 51 11 14 24 11 11 11 25 21 11 22 12 24 53 55 53 53 13 55 41 15 15 55 35 36 56 34 83 18 12 28 13 32 83 13 78 86 86 16 85 24 14 26 24 22 22 42 24 13 24 21 41 22 22 24 44 42 22 41 86 36 33 16 35 48 85 37 23 83 83 33 13 63 33 64 14 22 14 42 24 43 14 22 43 11 11 23 33 14 24 12 33 23 23 23 21 33 31 23 32 33 33 22 33 23 23 22 25 21 11 13 19 18 16 17 15 9 13 11 5 6 7 9 11 12 13 20 21 23 32 33 Marker order: 11 11 36 11 11 15 11 42 12 12 15 Telomere 54 54 54 55 33 35 53 54 54 53 53 38 38 32 18 32 13 12 37 17 18 68 D2S1352 IV 12 12 11 22 43 21 23 14 24 24 44 36 36 43 36 58 34 38 72 32 31 31 D2S2352 42 42 13 12 43 24 23 24 24 23 33 D2S378 33 33 32 23 13 23 23 33 23 23 23 D2S2279 D2S2183 Positive on tests for dyslexia + history of reading problems D2S1337 D2S393 Positive tests only Positive history only Centromere Figure 1 Pedigree showing only family members who were included in the linkage analysis. Pedigree numbers from the complete pedigree are retained. The numbers given above the symbol are the ages at the time the study was initiated. The proband (III.9) is indicated by an arrow. Boxed haplotypes indicate the haplotype cosegregating with dyslexia. Two critical recombinants were observed in adult patients (II.1, III.7) and their oVspring (III.3,IV.9) establishing the DYX3 candidate between markers D2S2352 and D2S1337. In generation IV,IV.7to IV.33,who were below the age of 20, were excluded from the model 3 linkage analysis. Chromosome analysis of III.31 was normal. that age and that the plasticity of these complex genes may be involved. In order to identify neural networks permits their adaptive reor- possible additional genes predisposing to ganisation. In contrast, the majority of teenag- dyslexia, we have carried out a genome search ers who experience comparable brain damage and performed linkage analysis in a large Nor- http://jmg.bmj.com/ never recover normal language function.10 A wegian family in which dyslexia is clearly molecular test, or tests, for dyslexia, which inherited. The pedigree is shown in fig 1. would result from cloning genes for dyslexia, would allow earlier diagnosis of children at Methods high risk for dyslexia. This in turn would TESTS FOR DYSLEXIA permit institution of therapy while the lan- The test instrument used to test for dyslexia in guage areas were at an earlier, more plastic the Norwegian population was developed at stage of development. the National Center for Reading Research. The on September 24, 2021 by guest. Protected copyright. The localisation of a susceptibility locus for assessments of both orthographic and phono- dyslexia to 6p21.311 has been confirmed in logical abilities are very similar to those used in three independent studies.12–14 Localisation to the genetic studies of Olson et al23 and the 6p, however, was not found in a large sib pair Woodcock Reading Mastery Tests.24 However, study,15 or in the large family studied by Sawyer a measure of reaction time was also included in et al.16 The linkage with chromosome 15p three of the tests. markers reported in 198317 was not initially The present dyslexia test battery was based confirmed,11 18 19 but two recent reports suggest on selected subtests from a series of tests given a localisation to D15S143, with lod scores of to Norwegian school children with possible 3.1512 and 1.38.20 This marker, however, is 49 reading problems to test their reading level and cM distal to the centromere and thus does not ability (KOAS25 and KOAP26).
Recommended publications
  • FK506-Binding Protein 12.6/1B, a Negative Regulator of [Ca2+], Rescues Memory and Restores Genomic Regulation in the Hippocampus of Aging Rats
    This Accepted Manuscript has not been copyedited and formatted. The final version may differ from this version. A link to any extended data will be provided when the final version is posted online. Research Articles: Neurobiology of Disease FK506-Binding Protein 12.6/1b, a negative regulator of [Ca2+], rescues memory and restores genomic regulation in the hippocampus of aging rats John C. Gant1, Eric M. Blalock1, Kuey-Chu Chen1, Inga Kadish2, Olivier Thibault1, Nada M. Porter1 and Philip W. Landfield1 1Department of Pharmacology & Nutritional Sciences, University of Kentucky, Lexington, KY 40536 2Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35294 DOI: 10.1523/JNEUROSCI.2234-17.2017 Received: 7 August 2017 Revised: 10 October 2017 Accepted: 24 November 2017 Published: 18 December 2017 Author contributions: J.C.G. and P.W.L. designed research; J.C.G., E.M.B., K.-c.C., and I.K. performed research; J.C.G., E.M.B., K.-c.C., I.K., and P.W.L. analyzed data; J.C.G., E.M.B., O.T., N.M.P., and P.W.L. wrote the paper. Conflict of Interest: The authors declare no competing financial interests. NIH grants AG004542, AG033649, AG052050, AG037868 and McAlpine Foundation for Neuroscience Research Corresponding author: Philip W. Landfield, [email protected], Department of Pharmacology & Nutritional Sciences, University of Kentucky, 800 Rose Street, UKMC MS 307, Lexington, KY 40536 Cite as: J. Neurosci ; 10.1523/JNEUROSCI.2234-17.2017 Alerts: Sign up at www.jneurosci.org/cgi/alerts to receive customized email alerts when the fully formatted version of this article is published.
    [Show full text]
  • SPATA33 Localizes Calcineurin to the Mitochondria and Regulates Sperm Motility in Mice
    SPATA33 localizes calcineurin to the mitochondria and regulates sperm motility in mice Haruhiko Miyataa, Seiya Ouraa,b, Akane Morohoshia,c, Keisuke Shimadaa, Daisuke Mashikoa,1, Yuki Oyamaa,b, Yuki Kanedaa,b, Takafumi Matsumuraa,2, Ferheen Abbasia,3, and Masahito Ikawaa,b,c,d,4 aResearch Institute for Microbial Diseases, Osaka University, Osaka 5650871, Japan; bGraduate School of Pharmaceutical Sciences, Osaka University, Osaka 5650871, Japan; cGraduate School of Medicine, Osaka University, Osaka 5650871, Japan; and dThe Institute of Medical Science, The University of Tokyo, Tokyo 1088639, Japan Edited by Mariana F. Wolfner, Cornell University, Ithaca, NY, and approved July 27, 2021 (received for review April 8, 2021) Calcineurin is a calcium-dependent phosphatase that plays roles in calcineurin can be a target for reversible and rapidly acting male a variety of biological processes including immune responses. In sper- contraceptives (5). However, it is challenging to develop molecules matozoa, there is a testis-enriched calcineurin composed of PPP3CC and that specifically inhibit sperm calcineurin and not somatic calci- PPP3R2 (sperm calcineurin) that is essential for sperm motility and male neurin because of sequence similarities (82% amino acid identity fertility. Because sperm calcineurin has been proposed as a target for between human PPP3CA and PPP3CC and 85% amino acid reversible male contraceptives, identifying proteins that interact with identity between human PPP3R1 and PPP3R2). Therefore, identi- sperm calcineurin widens the choice for developing specific inhibitors. fying proteins that interact with sperm calcineurin widens the choice Here, by screening the calcineurin-interacting PxIxIT consensus motif of inhibitors that target the sperm calcineurin pathway. in silico and analyzing the function of candidate proteins through the The PxIxIT motif is a conserved sequence found in generation of gene-modified mice, we discovered that SPATA33 inter- calcineurin-binding proteins (8, 9).
    [Show full text]
  • Single Nucleotide Polymorphisms Within Calcineurin-Encoding Genes
    Annals of Applied Sport Science, vol. 4, no. 2, pp. 01-08, Summer 2016 DOI: 10.18869/acadpub.aassjournal.4.2.1 Original Article www.aassjournal.com www.AESAsport.com ISSN (Online): 2322 – 4479 Received: 06/03/2016 ISSN (Print): 2476–4981 Accepted: 26/06/2016 Single Nucleotide Polymorphisms within Calcineurin-Encoding Genes are Associated with Response to Aerobic Training in Han Chinese Males 1Rong-mei Xu, 2Tao Lu, 2Lingxian Yan, 1Qinghua Song* 1The Center of Physical Health, Henan Polytechnic University, Jiaozuo 454000, Henan Province, China. 2 The Lab of Human Body Science, Henan Polytechnic University, Jiaozuo 454000, Henan Province, China. ABSTRACT Calcineurin, which functions in calcium signaling, is expressed in skeletal and cardiac muscle and has been linked to sensitivity to muscle strength training. It is also proposed to contribute to individual aerobic endurance. To investigate the relationship between calcineurin-encoding genes and aerobic endurance traits, 126 young-adult Han Chinese males were enrolled in an aerobic exercise training study. Participants were genotyped for polymorphisms within the 5 genes (PPP3CA, PPP3CB, PPP3CC, PPP3R1 and PPP3R2) encoding calcineurin using restriction fragment length polymorphism polymerase chain reaction (PCR-RFLP) or matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). Participants underwent 18 weeks of aerobic exercise training (running). Before and after the training period, maximal oxygen uptake (VO2max) and 12 km/h running economy were measured. Statistical analyses were performed using chi-square test and analysis of variance. The baseline value of VO2max was significantly associated with rs3804423 and rs2850965 loci in the PPP3CA gene (P<0.05).
    [Show full text]
  • 36-2997: Anti-Calcineurin B / PPP3R1 Monoclonal Antibody(Clone: CALNB/2342)
    9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982 Email: [email protected] 36-2997: Anti-Calcineurin B / PPP3R1 Monoclonal Antibody(Clone: CALNB/2342) Clonality : Monoclonal Clone Name : CALNB/2342 Application : IHC Reactivity : Human Gene : PPP3R1 Gene ID : 5534 Uniprot ID : P63098 Calcineurin B, type I (19kDa); Calcineurin subunit B type 1; CALNB1; CNB1; PPP3R1 protein Alternative Name : phosphatase 3 (formerly 2B), regulatory subunit B, alpha isoform; Protein phosphatase 3 regulatory subunit B alpha; Protein phosphatase 3 regulatory subunit B alpha isoform 1 Isotype : Mouse IgG1, kappa Immunogen Information : Recombinant full-length Calcineurin B protein Description Calcineurin is an enzyme that dephosphorylates serine and threonine residues in proteins. It is a heterodimer of a 59kDa catalytic A subunit and a 19kDa regulatory B subunit that is activated by the binding of calcium ions and calmodulin. Calcineurin is expressed in many tissues, but its levels are highest in the brain, where it may play a role in learning and memory. It has many substrates, including NFAT, a transcription factor that is activated by dephosphorylation. Complexes of the immuno- suppressants cyclosporine and FK506 with immunophilin proteins such as cyclophilin and FKBP12 are potent and specific inhibitors of Calcineurin activity. Alterations in Calcineurin activity are suspected to play a role in cardiac hypertrophy and graft versus host disease in organ transplantation. Product Info Amount : 20 µg / 100 µg 200 µg/ml of Ab Purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with Content : 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.
    [Show full text]
  • Molecular Network Approach Reveals Rictor As a Central Target of Cardiac Protectomirs
    International Journal of Molecular Sciences Article Molecular Network Approach Reveals Rictor as a Central Target of Cardiac ProtectomiRs András Makkos 1,2 , Bence Ágg 1,2,3 , Zoltán V. Varga 1,4 , Zoltán Giricz 1 , Mariann Gyöngyösi 5 , Dominika Lukovic 5, Rainer Schulz 6 , Monika Barteková 7,8 , Anikó Görbe 1,2,3,*,† and Péter Ferdinandy 1,2,3,† 1 Cardiovascular and Metabolic Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, 1089 Budapest, Hungary; [email protected] (A.M.); [email protected] (B.Á.); [email protected] (Z.V.V.); [email protected] (Z.G.); [email protected] (P.F.) 2 MTA-SE System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, 1089 Budapest, Hungary 3 Pharmahungary Group, 6722 Szeged, Hungary 4 HCEMM-SU Cardiometabolic Immunology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, 1089 Budapest, Hungary 5 Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria; [email protected] (M.G.); [email protected] (D.L.) 6 Institute of Physiology, Justus Liebig University Giessen, 35392 Giessen, Germany; [email protected] 7 Institute for Heart Research, Centre of Experimental Medicine, Slovak Academy of Sciences, Dúbravská cesta 9, 84104 Bratislava, Slovakia; [email protected] 8 Institute of Physiology, Comenius University in Bratislava, 81108 Bratislava, Slovakia * Correspondence: [email protected] Citation: Makkos, A.; Ágg, B.; Varga, † These authors contributed equally. Z.V.; Giricz, Z.; Gyöngyösi, M.; Lukovic, D.; Schulz, R.; Barteková, M.; Görbe, A.; Ferdinandy, P.
    [Show full text]
  • Human PPP3R1 / Calcineurin B (1-170, His-Tag) - Purified
    OriGene Technologies, Inc. OriGene Technologies GmbH 9620 Medical Center Drive, Ste 200 Schillerstr. 5 Rockville, MD 20850 32052 Herford UNITED STATES GERMANY Phone: +1-888-267-4436 Phone: +49-5221-34606-0 Fax: +1-301-340-8606 Fax: +49-5221-34606-11 [email protected] [email protected] AR09841PU-L Human PPP3R1 / Calcineurin B (1-170, His-tag) - Purified Alternate names: CNA2, CNB, Calcineurin subunit B type 1, PP2B regulatory subunit 1, Protein phosphatase 2B regulatory subunit 1, Protein phosphatase 2B regulatory subunit 1, Protein phosphatase 3 regulatory subunit B alpha isoform 1 Quantity: 0.5 mg Concentration: 1.0 mg/ml (determined by Bradford assay) Background: PPP3R1, also known as Calcineurin subunit B type 1, is a Ser/Thr-specific calcium and calmodulin-dependent protein phosphatase that plays an essential role in the T cell activation pathway. Calcineurin is composed of two subunits; calcineurin A (CnA) and calcineurin B (CnB). Dephosphorylation of the nuclear factor of activated T-cells (NF- AT) by Calcineurin is essential for NF-AT activation, nuclear translocation, and early gene expression in T-cells. Uniprot ID: P63098 NCBI: NP_000936 GeneID: 5534 Species: Human Source: E. coli Format: State: Liquid purified protein Purity: >90% Buffer System: 20mM Tris-HCl buffer (pH 8.0) containing 10% glycerol, 2mM DTT, 0.1M NaCl Description: Recombinant human PPP3R1 protein, fused to His-tag at N-terminus, was expressed in E.coli and purified by using conventional chromatography techniques. AA Sequence: MGSSHHHHHH SSGLVPRGSH MGNEASYPLE MCSHFDADEI KRLGKRFKKL DLDNSGSLSV EEFMSLPELQ QNPLVQRVID IFDTDGNGEV DFKEFIEGVS QFSVKGDKEQ KLRFAFRIYD MDKDGYISNG ELFQVLKMMV GNNLKDTQLQ QIVDKTIINA DKDGDGRISF EEFCAVVGGL DIHKKMVVDV Molecular weight: 21.5 kDa (190aa), confirmed by MALDI-TOF Storage: Store undiluted at 2-8°C for up to two weeks or (in aliquots) at -20°C or -70°C for longer.
    [Show full text]
  • Genome Wide Analysis Approach Suggests Chromosome 2 Locus to Be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response Sonal Singh1, Caitrin W
    www.nature.com/scientificreports OPEN Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response Sonal Singh1, Caitrin W. McDonough1, Yan Gong1, Kent R. Bailey2, Eric Boerwinkle3, Arlene B. Chapman4, John G. Gums1, Stephen T. Turner5, Rhonda M. Cooper-DeHof1,6 & Julie A. Johnson 1,6* Chlorthalidone (CTD) is more potent than hydrochlorothiazide (HCTZ) in reducing blood pressure (BP) in hypertensive patients, though both are plagued with BP response variability. However, there is a void in the literature regarding the genetic determinants contributing to the variability observed in BP response to CTD. We performed a discovery genome wide association analysis of BP response post CTD treatment in African Americans (AA) and European Americans (EA) from the Pharmacogenomic Evaluation of Antihypertensive Responses-2 (PEAR-2) study and replication in an independent cohort of AA and EA treated with HCTZ from the PEAR study, followed by a race specifc meta-analysis of the two studies. Successfully replicated SNPs were further validated in beta-blocker treated participants from PEAR-2 and PEAR for opposite direction of association. The replicated and validated signals were further evaluated by protein-protein interaction network analysis. An intronic SNP rs79237970 in the WDR92 (eQTL for PPP3R1) was signifcantly associated with better DBP response to CTD (p = 5.76 × 10−6, β = −15.75) in the AA cohort. This SNP further replicated in PEAR (p = 0.00046, β = −9.815) with a genome wide signifcant meta-analysis p-value of 8.49 × 10−9. This variant was further validated for opposite association in two β-blockers treated cohorts from PEAR-2 metoprolol (p = 9.9 × 10−3, β = 7.47) and PEAR atenolol (p = 0.04, β = 4.36) for association with DBP.
    [Show full text]
  • The Human Gene Connectome As a Map of Short Cuts for Morbid Allele Discovery
    The human gene connectome as a map of short cuts for morbid allele discovery Yuval Itana,1, Shen-Ying Zhanga,b, Guillaume Vogta,b, Avinash Abhyankara, Melina Hermana, Patrick Nitschkec, Dror Friedd, Lluis Quintana-Murcie, Laurent Abela,b, and Jean-Laurent Casanovaa,b,f aSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065; bLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U980, Necker Medical School, 75015 Paris, France; cPlateforme Bioinformatique, Université Paris Descartes, 75116 Paris, France; dDepartment of Computer Science, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel; eUnit of Human Evolutionary Genetics, Centre National de la Recherche Scientifique, Unité de Recherche Associée 3012, Institut Pasteur, F-75015 Paris, France; and fPediatric Immunology-Hematology Unit, Necker Hospital for Sick Children, 75015 Paris, France Edited* by Bruce Beutler, University of Texas Southwestern Medical Center, Dallas, TX, and approved February 15, 2013 (received for review October 19, 2012) High-throughput genomic data reveal thousands of gene variants to detect a single mutated gene, with the other polymorphic genes per patient, and it is often difficult to determine which of these being of less interest. This goes some way to explaining why, variants underlies disease in a given individual. However, at the despite the abundance of NGS data, the discovery of disease- population level, there may be some degree of phenotypic homo- causing alleles from such data remains somewhat limited. geneity, with alterations of specific physiological pathways under- We developed the human gene connectome (HGC) to over- come this problem.
    [Show full text]
  • Supplementary Table S1. List of Differentially Expressed
    Supplementary table S1. List of differentially expressed transcripts (FDR adjusted p‐value < 0.05 and −1.4 ≤ FC ≥1.4). 1 ID Symbol Entrez Gene Name Adj. p‐Value Log2 FC 214895_s_at ADAM10 ADAM metallopeptidase domain 10 3,11E‐05 −1,400 205997_at ADAM28 ADAM metallopeptidase domain 28 6,57E‐05 −1,400 220606_s_at ADPRM ADP‐ribose/CDP‐alcohol diphosphatase, manganese dependent 6,50E‐06 −1,430 217410_at AGRN agrin 2,34E‐10 1,420 212980_at AHSA2P activator of HSP90 ATPase homolog 2, pseudogene 6,44E‐06 −1,920 219672_at AHSP alpha hemoglobin stabilizing protein 7,27E‐05 2,330 aminoacyl tRNA synthetase complex interacting multifunctional 202541_at AIMP1 4,91E‐06 −1,830 protein 1 210269_s_at AKAP17A A‐kinase anchoring protein 17A 2,64E‐10 −1,560 211560_s_at ALAS2 5ʹ‐aminolevulinate synthase 2 4,28E‐06 3,560 212224_at ALDH1A1 aldehyde dehydrogenase 1 family member A1 8,93E‐04 −1,400 205583_s_at ALG13 ALG13 UDP‐N‐acetylglucosaminyltransferase subunit 9,50E‐07 −1,430 207206_s_at ALOX12 arachidonate 12‐lipoxygenase, 12S type 4,76E‐05 1,630 AMY1C (includes 208498_s_at amylase alpha 1C 3,83E‐05 −1,700 others) 201043_s_at ANP32A acidic nuclear phosphoprotein 32 family member A 5,61E‐09 −1,760 202888_s_at ANPEP alanyl aminopeptidase, membrane 7,40E‐04 −1,600 221013_s_at APOL2 apolipoprotein L2 6,57E‐11 1,600 219094_at ARMC8 armadillo repeat containing 8 3,47E‐08 −1,710 207798_s_at ATXN2L ataxin 2 like 2,16E‐07 −1,410 215990_s_at BCL6 BCL6 transcription repressor 1,74E‐07 −1,700 200776_s_at BZW1 basic leucine zipper and W2 domains 1 1,09E‐06 −1,570 222309_at
    [Show full text]
  • Snps Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer’S Disease
    SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer’s Disease Carlos Cruchaga1,2.*, John S. K. Kauwe3., Kevin Mayo1,2, Noah Spiegel1,2, Sarah Bertelsen1, Petra Nowotny1,2, Aarti R. Shah2,4, Richard Abraham9, Paul Hollingworth5, Denise Harold5, Michael M. Owen5, Julie Williams5, Simon Lovestone6, Elaine R. Peskind7,8,GeLi7,8, James B. Leverenz7,8,9, Douglas Galasko10, The Alzheimer’s Disease Neuroimaging Initiative", John C. Morris4,11,6, Anne M. Fagan2,4,13, David M. Holtzman2,4,12,13, Alison M. Goate1,2,4,13 1 Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, United States of America, 2 The Hope Center Program on Protein Aggregation and Neurodegeneration (HPAN), Washington University School of Medicine, St. Louis, Missouri, United States of America, 3 Department of Biology, Brigham Young University, Provo, Utah, United States of America, 4 Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States of America, 5 Department of Psychological Medicine, Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, United Kingdom, 6 Kings College, London, United Kingdom, 7 Departments of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington, United States of America, 8 Veterans Affairs Northwest Network Mental Illness Research, Education, and Clinical Center, Seattle, Washington, United States of America, 9 Department of Neurology, University of Washington School of Medicine, Seattle, Washington, United States of America, 10 Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America, 11 Department of Pathology and Immunology, Washington University School of Medicine, St.
    [Show full text]
  • Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors
    University of Cincinnati Date: 12/20/2010 I, Arturo R Maldonado , hereby submit this original work as part of the requirements for the degree of Doctor of Philosophy in Developmental Biology. It is entitled: Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors Student's name: Arturo R Maldonado This work and its defense approved by: Committee chair: Jeffrey Whitsett Committee member: Timothy Crombleholme, MD Committee member: Dan Wiginton, PhD Committee member: Rhonda Cardin, PhD Committee member: Tim Cripe 1297 Last Printed:1/11/2011 Document Of Defense Form Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors A dissertation submitted to the Graduate School of the University of Cincinnati College of Medicine in partial fulfillment of the requirements for the degree of DOCTORATE OF PHILOSOPHY (PH.D.) in the Division of Molecular & Developmental Biology 2010 By Arturo Rafael Maldonado B.A., University of Miami, Coral Gables, Florida June 1993 M.D., New Jersey Medical School, Newark, New Jersey June 1999 Committee Chair: Jeffrey A. Whitsett, M.D. Advisor: Timothy M. Crombleholme, M.D. Timothy P. Cripe, M.D. Ph.D. Dan Wiginton, Ph.D. Rhonda D. Cardin, Ph.D. ABSTRACT Since 1999, cancer has surpassed heart disease as the number one cause of death in the US for people under the age of 85. Malignant Peripheral Nerve Sheath Tumor (MPNST), a common malignancy in patients with Neurofibromatosis, and colorectal cancer are midkine- producing tumors with high mortality rates. In vitro and preclinical xenograft models of MPNST were utilized in this dissertation to study the role of midkine (MDK), a tumor-specific gene over- expressed in these tumors and to test the efficacy of a MDK-transcriptionally targeted oncolytic HSV-1 (oHSV).
    [Show full text]
  • Anti-PPP3CB (Aa 63-363) Polyclonal Antibody (DPABH-19613) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use
    Anti-PPP3CB (aa 63-363) polyclonal antibody (DPABH-19613) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Antigen Description Calcium-dependent, calmodulin-stimulated protein phosphatase. This subunit may have a role in the calmodulin activation of calcineurin. Immunogen Recombinant fragment, corresponding to a region within amino acids 63-363 of Human PPP3CB (NP_066955). Isotype IgG Source/Host Rabbit Species Reactivity Mouse, Human Purification Immunogen affinity purified Conjugate Unconjugated Applications WB Format Liquid Size 50 μl Buffer Constituents: 10% Glycerol, 0.1M Tris, 0.1M Glycine, pH 7.0 Preservative None Storage Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. GENE INFORMATION Gene Name PPP3CB protein phosphatase 3, catalytic subunit, beta isozyme [ Homo sapiens ] Official Symbol PPP3CB Synonyms PPP3CB; protein phosphatase 3, catalytic subunit, beta isozyme; CALNB, protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform; protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform (calcineurin A beta); serine/threonine-protein phosphatase 2B catalytic subunit beta isoform; calcineurin A beta; CALNA2; CNA2; PP2Bbeta; protein phosphatase 2B; 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved catalytic subunit; beta isoform; calcineurin A2; CAM-PRP catalytic subunit; protein phosphatase from PCR fragment H32; calmodulin-dependent
    [Show full text]